12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RP5063: Completed Phase II enrollment

Reviva completed enrollment of 234 schizophrenia patients in the double-blind, placebo-controlled, international Phase II REFRESH trial comparing 15, 30 or 50 mg daily RP5063 vs. 15 mg daily aripiprazole. ...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >